Particular caution should be exercised to patients at increased risk or diagnosed with medullary thyroid cancer or mutations in the RET proto-oncogene and multiple endocrine neoplasia type 2 (MEN2), as well as with a family history of the disease (Figure 4). This evidence concerns the gene RET and medullary thyroid gland carcinoma.